Online inquiry

IVTScrip™ mRNA-Human ATP2B4, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK27592MR)

This product GTTS-WK27592MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the ATP2B4 protein. This product can be used in Sertoli cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001001396.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 493
UniProt ID P23634
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ATP2B4, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WK27592MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK8151MR IVTScrip™ mRNA-Human ABCC9, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABCC9
GTTS-WK16075MR IVTScrip™ mRNA-Human Androgen-binding protein, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Androgen-binding protein
GTTS-WK21916MR IVTScrip™ mRNA-Human APOA2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APOA2
GTTS-WK24950MR IVTScrip™ mRNA-Human AQP5, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AQP5
GTTS-WK4188MR IVTScrip™ mRNA-Human MGARP, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGARP
GTTS-WK15189MR IVTScrip™ mRNA-Human ANKHD1-EIF4EBP3, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKHD1-EIF4EBP3
GTTS-WK11457MR IVTScrip™ mRNA-Human ABCG1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABCG1
GTTS-WK15889MR IVTScrip™ mRNA-Human AP3S1, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AP3S1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW